Dicerna Finds RNAi-Savvy Partner in Kyowa for Cancer Drug Program | GenomeWeb

By Doug Macron

Dicerna Pharmaceuticals this week announced that it has signed a deal with Japanese pharmaceutical giant Kyowa Hakko Kirin to develop an RNAi-based cancer drug.

Having consummated the deal in December, Dicerna met its longstanding goal of forging at least one industry partnerships in 2009. At the same time, the company has found in Kyowa a big pharma ally with experience in the RNAi therapeutics field.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Science this week: ancient Ethiopian genome indicates greater Eurasian backflow into Africa, sequencing to diagnose cutaneous T cell lymphoma, and more.

The US House of Representatives science committee has passed a bill to require NSF to ensure it only funds projects that are in the national interest.

DuPont teams with genome editing firm Caribou Biosciences for agricultural applications of the technology.

A blogger reviews her experience learning about her gut microbiome by shipping a sample to uBiome.